Safety, tolerability and pharmacokinetics of intra‐articular (IA) single ascending dose of 4P‐004 in patient with Kellgren and Lawrence grade 2 to 4 osteoarthritic (OA) knee

2022-500271-31-00 Protocol 4MB-LAS-P Human pharmacology (Phase I) - Other Ended

Start 10 May 2023 · End 31 Oct 2023 · Status Ended · 1 EU/EEA countries · 4 sites · Protocol 4MB-LAS-P

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 32
Countries 1
Sites 4

Knee osteoarthritis

Key facts

Sponsor
4moving Biotech
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Musculoskeletal Diseases [C05]
Trial duration
10 May 2023 → 31 Oct 2023
Decision date (initial)
2022-06-23
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Knee osteoarthritis

VersionLevelCodeTermSystem organ class
20.0 PT 10031161 Osteoarthritis 100000004859

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

4moving Biotech

Sponsor organisation
4moving Biotech
Address
Campus De L'institut Pasteur De Lille, 1 Rue Du Professeur Calmette 1 Rue Du Professeur Calmette
City
Lille
Postcode
59800
Country
France

Scientific contact point

Organisation
4moving Biotech
Contact name
Francis Berenbaum

Public contact point

Organisation
4moving Biotech
Contact name
Francis Berenbaum

Locations

1 EU/EEA country · 4 investigational sites

By country

CountryMS statusPlanned subjectsSites
Belgium Ended 32 4
Rest of world 0

Investigational sites

Belgium

4 sites · Ended
Az Maria Middelares Gent
Orthopedics, Buitenring-Sint-Denijs 30, 9000, Gent
UZ Leuven
Head of Clinic, department of Rheumatology, University Hospitals, Leuven, Belgium, Herestraat 49, 3000, Leuven
Cliniques Universitaires Saint-Luc
Head of clinic of orthopeadic and traumatology, Hippokrateslaan 10, Batiment 54, Sint-Lambrechts-Woluwe
Medisch Centrum Latem
Knee clinic, Kortrijksesteenweg 53, 9830, Sint-Martens-Latem

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Belgium 2022-09-26 2023-10-31 2022-09-26 2023-10-03

Oversight and notifications

Regulatory notifications under CTR Articles 38, 52, 53, 54 and 77

Temporary halts 1 · Art. 38 CTR

Temporary halt TH-1659

Halt date
2023-04-18
Planned restart
2023-05-16
Member states concerned
Belgium
Publication date
2023-05-09
Reason
Investigator/Site related, Sponsor decision
Benefit-risk balance changed
No
Treatment stopped
No

Application history

5 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2022-05-06 Belgium Acceptable
2022-06-23
2022-06-23
2 NON SUBSTANTIAL MODIFICATION NSM-2 2023-05-16 Belgium Acceptable
2022-06-23
2023-05-16
3 SUBSTANTIAL MODIFICATION SM-5 2023-07-18 Belgium Acceptable
2023-08-01
2023-08-18
4 SUBSTANTIAL MODIFICATION SM-7 2023-09-04 Belgium Acceptable 2023-09-18
5 NON SUBSTANTIAL MODIFICATION NSM-3 2023-09-21 Belgium Acceptable 2023-09-21